N/A N=245 Transmission of Coronavirus Disease 2019 (COVID19) in Crowded Environments
Covid19 · Sars-CoV-2 Infection
Primary: SARS-CoV-2 Infection — 4; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=4,142 COVID-19: Human Epidemiology and Response to SARS-CoV-2
Coronavirus Disease 2019 (COVID-19) · SARS-CoV-2
Primary: Number of Index Participants and Their Household Contacts With SARS-CoV-2 RNA Detection in Nasal Samples Over the Study/Surveillance Period — 98.9; 99.2; 99.1; 98.0…
N/A N=112 Coronavirus Disease of 2019 (COVID-19) Health Education Initiative for School Safety
COVID-19
Primary: Evaluation of Acceptability of Intervention as Measured by Acceptability Questionnaire — 4.47 score on a scale
Phase 1 N=18 This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)
SARS-CoV-2 Infection
Primary: Number of Patients With TEAEs — 3; 4; 3; 1 Participants
Phase 3 N=3,411 CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION
COVID 19
Primary: Number of Participants With Symptomatic COVID-19 at 60 Days — 24; 19 Participants — p=0.52
N/A N=15 Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus)
Coronavirus
Primary: Deterioration Resulting in Healthcare Review — 10 alerts generated
N/A N=118 Study to Evaluate Efficacy and Safety of "VIRACIDE" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)
Covid19
Primary: Number of Participants With National Early Warning Score (NEWS) Change From 3 to 0 — 44; 29 Participants
N/A N=2,598 HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV
HIV-1-infection · COVID-19
Primary: Number of Composite Primary End Point (Critical Care Admission, Palliative Discharge When Discharged From Hospital, or Mortality Within the 6 Weeks After Diagnosis of…
Phase 2 N=124 Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)
Coronavirus Disease 2019 (COVID-19)
Primary: The Percent of Participants With Tracheal Intubation or Death Prior to Tracheal Intubation — 26.2; 22.2 percentage of participants
Phase 1 N=150 N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19)
Coronavirus · Covid19
Primary: Number of Participants Intubated During Hospitalization — 8; 25 Participants — p=0.297
Phase 2 N=47 Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19)
COVID-19
Primary: Number of Participants Requiring Mechanical Ventilation or Dying — 3; 3 Participants
Phase 2 N=41 Nebulised Dornase Alfa for Treatment of COVID-19 (Coronavirus Disease 2019)
COVID-19 (Coronavirus Disease 2019) · Hypoxia
Primary: Measuring the Change in Inflammation — 23.23; 34.82 mg/L — p=0.01
N/A N=69 Detection of SARS-CoV-2 RNA in Coughed Droplets From Patients With COVID-19
Covid19
Primary: Sensitivity of Detecting SARS-CoV-2 RNA — 31; 0 Participants
Phase 2 N=180 Convalescent Plasma to Stem Coronavirus (CSSC-001)
Coronavirus · Convalescence
Primary: Efficacy of Treatment at Day 28 as Assessed by Number of Participants Who Develop SARS-Cov-2 Infection — 12; 13 Participants — p=0.42
N/A N=7,444 Mental and Physical Well-Being of Frontline Health Care Workers During Coronavirus Disease 2019 (COVID-19)
Healthy
Primary: PTSD Symptom Severity — 16.36; 17.10; 15.56; 15.78 score on a scale — p=.77
N/A N=9 Use of Continuous Glucose Monitors in Coronavirus Disease 2019 ICU and Potential Inpatient Settings
Covid19 · Diabetes Mellitus
Primary: Time in Range — 21.6 percentage of time
Phase 3 N=49 Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients
COVID-19
Primary: Number of Subjects Experiencing TEAEs — 16; 12; 9; 2 Participants
Phase 2 N=181 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
Covid19
Primary: Change From Baseline to Day 8 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Shedding — -2.88; -3.52; -3.75; -3.03 log10 copies/ml — p=0.4829
Phase 3 N=220 A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)
COVID-19
Primary: Proportion of Patients Without Any Need for INV Until EoS — 98; 101; 12; 9 Participants
Phase 2 N=25 Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19
Covid19 · Pneumonia, Viral
Primary: Count of White Blood Cells (WBC) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With…
Phase 3 N=239 Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI
Corona Virus Infection
Primary: Percentage of Participants With WHO Clinical Progression Scale > 5 at Day 4 -- Severe COVID Population (WHO Clinical Progression Scale =5 at Baseline) — 26; 26…
N/A N=270 The Impact of the COVID-19 (SARS-CoV-2 Disease) on Psychopathology
Psychosis;Schizophrenic · Personality Disorders · Mood Disorders
Primary: Brief Psychiatric Rating Scale (BPRS) — 29.30; 32.80; 30.25 score on a scale
Phase 4 N=50 Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease
Increased Risk of SARS-CoV-2 Infection
Primary: Negative Polymerase Chain Reaction (PCR) — 2; 7 Participants
Phase 2 N=99 Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19
COVID · Corona Virus Infection · Covid-19
Primary: Percent Change in D-dimer — -5.6; -2.4 percent daily change — p=0.24
Phase 3 N=4,838 Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)
COVID-19
Primary: Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 14 — 8.0; 10.7; 8.5; 16.8 percentage of participants…
Phase 3 N=400 Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection
Covid19
Primary: Number of Patients With Early Clinical Improvement — 111; 80 Participants — p=<0.03
Phase 3 N=771 Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients
Coronavirus Disease 2019 (COVID-19)
Primary: Number of Participants With COVID-19 Progression to a More Severe Form — 59; 89 Participants — p=0.0088
N/A N=300 Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19).
Androgenetic Alopecia · Coronavirus Disease 2019 · Covid19
Primary: Androgenetic Alopecia Frequency in Participants. — 209; 37; 11; 43 Participants
N/A N=820 The Doctors for Coronavirus Prevention Project Thanksgiving / Christmas Messaging Campaign
Covid19
Primary: Facebook Movement Metric — -6.082; -5.320; -2.603; -1.823 Percent change relative to Feb 2020
N/A N=28 Balance Function in Patients Post Corona Virus Disease 2019 (COVID-19)
Covid19
Primary: Motor Balance as Measured by Timed Up and Go (TUG) — 20.57 seconds